LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.98 7.01

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.16

Max

13.03

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+159.23% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-339M 1B
Vorige openingsprijs	5.97
Vorige sluitingsprijs	12.98

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mei 2026, 16:49 UTC

Winsten

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mei 2026, 16:26 UTC

Belangrijke Marktbewegers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mei 2026, 23:51 UTC

Marktinformatie

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mei 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mei 2026, 21:53 UTC

Winsten

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mei 2026, 21:02 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mei 2026, 20:55 UTC

Winsten

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mei 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mei 2026, 20:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 mei 2026, 20:20 UTC

Marktinformatie

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Adj EPS 3c >BULL

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Rev $159.9M >BULL

21 mei 2026, 20:18 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mei 2026, 20:18 UTC

Winsten

Webull 1Q Loss/Shr 4c

21 mei 2026, 19:43 UTC

Marktinformatie

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mei 2026, 18:58 UTC

Winsten

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mei 2026, 18:15 UTC

Marktinformatie

Gold Higher For Second Consecutive Day -- Market Talk

21 mei 2026, 17:40 UTC

Marktinformatie

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mei 2026, 17:04 UTC

Marktinformatie

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mei 2026, 17:01 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Stellantis Targets Distant but Constructive -- Market Talk

21 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

159.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 159.23%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.